Renal side effects of immune checkpoint inhibitors

doi:10.3877/cma.j.issn.2095-3216.2020.02.007

Abstract

Abstract:

Immunomodulation is an important determinant in controlling the progression of malignant tumors.The development of immune checkpoint inhibitors (ICIs) has revolutionized the treatments and significantly improved the survival of patients with cancer in less than a decade. Despite the remarkable clinical benefits of ICIs, they also bring the toxicity risk of immune-related adverse events. This article reviewed the mechanism, incidence, pathological types, diagnosis, and treatment strategies of ICIs- associated renal side effects.

Key words: Immunotherapy, Immune checkpoint inhibitors, Acute kidney injury, Acute interstitial nephritis

Zhongke Qin, Huijuan Mao. Renal side effects of immune checkpoint inhibitors[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2020, 09(02): 82-85.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2020.02.007

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2020/V09/I02/82

References 36

[1]	Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy [J]. J Clin Oncol, 2015, 33(17): 1974-1982.
[2]	Marin－Acevedo JA, Chirila RM, Dronca RS. Immune checkpoint inhibitor toxicities [J]. Mayo Clin Proc, 2019, 94(7): 1321-1329.
[3]	Gianchecchi E, Fierabracci A. Inhibitory receptors and pathways of lymphocytes: the role of PD－1 in treg development and their involvement in autoimmunity onset and cancer progression [J]. Front Immunol, 2018, 9: 2374.
[4]	Yokosuka T, Takamatsu M, Kobayashi－Imanishi W, et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 [J]. J Exp Med, 2012, 209(6): 1201-1217.
[5]	Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA－approved immune checkpoint inhibitors [J]. Int Immunopharmacol, 2018, 62: 29-39.
[6]	Nishimura H, Nose M, Hiai H, et al. Development of lupus－like autoimmune diseases by disruption of the PD－1 gene encoding an ITIM motif－carrying immunoreceptor [J]. Immunity, 1999, 11(2): 141-151.
[7]	Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla－4 [J]. Science, 1995, 270(5238): 985-988.
[8]	Matsui T, Kurokawa M, Kobata T, et al. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases [J]. J immunol, 1999, 162(7): 4328-4335.
[9]	Prokunina L, Castillejo－Lopez C, Oberg F, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans [J]. Nat Genet, 2002, 32(4): 666-669.
[10]	Menzies AM, Johnson DB, Ramanujam S, et al. Anti－PD－1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab [J]. Ann Oncol, 2017, 28(2): 368-376.
[11]	Abdel－Wahab N, Shah M, Suarez－Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports [J]. PLoS One, 2016, 11(7): e0160221.
[12]	Manohar S, Kompotiatis P, Thongprayoon C, et al. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta－analysis [J]. Nephrol Dial Transpl, 2019, 34(1): 108-117.
[13]	Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors [J]. Kidney Int, 2016, 90(3): 638-647.
[14]	Wanchoo R, Karam S, Uppal NN, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review [J]. Am J Nephrol, 2017, 45(2): 160-169.
[15]	Seethapathy H, Zhao S, Chute DF, et al. The incidence, causes and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors [J]. Clin J Am Soc Nephrol, 2019, 14(12): 1692-1700.
[16]	Shirali AC, Perazella MA, Gettinger S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients [J]. Am J Kidney Dis, 2016, 68(2): 287-291.
[17]	Murakami N, Borges TJ, Yamashita M, et al. Severe acute interstitial nephritis after combination immune－checkpoint inhibitor therapy for metastatic melanoma [J]. Clin Kidney J, 2016, 9(3): 411-417.
[18]	Fadel F, El Karoui K, Knebelmann B. Anti－CTLA4 antibody－induced lupus nephritis [J]. N Engl J Med, 2009, 361(2): 211-212.
[19]	Kidd JM, Gizaw AB. Ipilimumab－associated minimal－change disease [J]. Kidney Int, 2016, 89(3): 720-720.
[20]	Kitchlu A, Fingrut W, Avila－Casado C, et al. Nephrotic syndrome with cancer immunotherapies: a report of 2 cases [J]. Am J Kidney Dis, 2017, 70(4): 581-585.
[21]	Gallan AJ, Alexander E, Reid P, et al. Renal vasculitis and pauci－immune glomerulonephritis associated with immune checkpoint inhibitors [J]. Am J Kidney Dis, 2019, 74(6): 853-856.
[22]	Mamlouk O, Selamet U, Machado S, et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single－center experience [J]. J ImmunoTher Cancer, 2019, 7(1): 2.
[23]	Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune－related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma [J]. Cancer, 2013, 119(9): 1675-1682.
[24]	Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA－4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA－4 [J]. Immunity, 1995, 3(5): 541-547.
[25]	Zha Y, Blank C, Gajewski TF. Negative regulation of T－cell function by PD－1 [J]．Crit Rev Immunol, 2004, 24(4): 229-237.
[26]	Izzedine H, Mateus C, Boutros C, et al. Renal effects of immune checkpoint inhibitors [J]. Nephrol Dial Transplant, 2017, 32(6): 936-942.
[27]	Koda R, Watanabe H, Tsuchida M, et al. Immune checkpoint inhibitor (nivolumab)－associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report [J]. BMC Nephrology, 2018, 19(1): 48.
[28]	Spanou Z, Keller M, Britschgi M, et al. Involvement of drug－specific T cells in acute drug－induced interstitial nephritis [J]. J Am Soc Nephrol, 2006, 17(10): 2919-2927.
[29]	Sury K, Perazella MA. The nephrotoxicity of new immunotherapies [J]. Expert Rev Clin Pharmacol, 2019, 12(6): 513-521.
[30]	Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune－related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline [J]. J Clin Oncol, 2018, 36(17): 1714-1768.
[31]	Krishnan N, Perazella MA. Drug－induced acute interstitial nephritis pathology, pathogenesis and treatment [J]. Iran J Kidney Dis, 2015, 9(1): 3-13.
[32]	Sise ME, Seethapathy H, Reynolds KL. Diagnosis and management of immune checkpoint inhibitor－associated renal toxicity: illustrative case and review [J]. Oncologist, 2019, 24(6): 735-742.
[33]	Horvat TZ, Adel NG, Thu－Oanh D, et al. Immune－related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center [J]. J Clin Oncol, 2015, 33(28): 3193-3198.
[34]	Faje AT, Lawrence D, Flaherty K, et al. High－dose glucocorticoids for the treatment of ipilimumab－induced hypophysitis is associated with reduced survival in patients with melanoma [J]. Cancer, 2018, 124(18): 3706-3714.
[35]	Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials [J]. J Clin Oncol, 2017, 35(34): 3807-3814.
[36]	张小红，洪聪敏，邹臻寰，等. 急性肾损伤患者远期肾脏预后的分析[J]. 中华肾脏病杂志，2017, 33(11): 801-807.

Please choose a citation manager

Content to export